Publications

 


  • 713. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

    Pasanen N, Talala K, Remmers S, Tammela TLJ, Hugosson J, Roobol MJ, Taari K, Arnsrud Godtman R, Bangma CH, Auvinen A, 2024

    Journal: BJU Int
    Reference: 2024 May 9. doi: 10.1111/bju.16394.

    paper

  • 712. From screening to mortality reduction: an overview of emperical data on the patient journey in European Randomized Study of Screening for Prostate Cancer Rotterdam after 21 years of follow-up and a reflection on quality of life

    Hogenhout R, Remmers S, van Slooten-Midderigh ME, de Vos II, Roobol MJ, ERSPC Rotterdam Study Group, 2023

    Journal: Eur Urol Oncol
    Reference: 2023 Sep 8:S2588-9311(23)00172-4. doi: 10.1016/j.euo.2023.08.011.

    paper

  • 711. Prostate cancer mortality among elderly men after discontinuing organised screening: long-term results from the European Randomized Study of Screening for Prostate Cancer Rotterdam

    De Vos II, Remmers S, Hogenhout R, Roobol MJ. , 2024

    Journal: Eur Urol
    Reference: 2024 Jan;85(1):74-81. doi: 10.1016/j.eururo.2023.10.011.

    paper

  • 710. Statin use and outcomes of oncological treatment for castration-resistant prostate cancer

    Peltomaa AI, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ, 2023

    Journal: Sci Rep.
    Reference: 2023 Nov 1;13(1):18866. doi: 10.1038/s41598-023-45958-8.

    paper

  • 709. Screening history and risk of death from prostate cancer: a nested case-control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)

    Talala K, Walter S, Taari K, Tammela TLJ, Kujala P, Auvinen A., 2023

    Journal: Cancer Causes Control
    Reference: 2023 Dec 8. doi: 10.1007/s10552-023-01828-2.

    paper

  • 708. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

    Siltari A, Murtola TJ, Kausz J, Talala K, Taari K, Tammela TLJ, Auvinen A, 2023

    Journal: Acta Oncol.
    Reference: 2023 Dec;62(12):1898-1904. doi: 10.1080/0284186X.2023.2278189.

    paper

  • 707. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.

    Nygard LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. , 2023

    Journal: Prostate
    Reference: 2023 Feb;83(3):246-258. doi: 10.1002/pros.24456.

    paper

  • 706. Relationship between baseline prostate-specific antigen on cancer detection and prostate cancer death: long-term follow-up from the European Randomized study of Screening for Prostate Cancer

    Remmers S, Bangma CH, Godtman R, Carlsson SV, Auvinen A, Tammela TLJ, Denis LJ, Nelen V, Villers A, Rebillard X, Kwiatkowski M, Recker F, Wyler S, Zappa M, Puliti D, Gorini G, Paez A, Lujan M, Nieboer D, Schroder FH, Roobol MJ., 2023

    Journal: Eur Urol.
    Reference: Apr 21;S0302-2838(23)02709-4. doi:10.1016/j.eururo.2023.03.031.

    paper

  • 705. A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European Randomized study of Screening for Prostate Cancer

    de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group, 2023

    Journal: European Urology
    Reference: Apr 5;S0303-2838(23)02669-6. doi: 10.1016/j.eururo.2023.03.016.

    paper

  • 704. The patient journey from randomization to detection of prostate cancer and death: results from ERSPC Rotterdam

    Remmers S, Nieboer D, Roobol MJ, ERSPC Rotterdam Study Group, 2023

    Journal: European Urology Open Science
    Reference: 51:1-6; https://doi.org/10.1016/j.euros.2023.02.013.

    paper

  • 703. Young age on starting prostate-specific antigen testing is associated with a greater reduction in prostate cancer mortality: 24-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial

    Carlsson SV, Arnsrud Godtman R, Pihl C-G, Vickers A, Lilja H, Hugosson J, Mansson M, 2022

    Journal: Eur Urol
    Reference: 2022 Nov 2;S0302-2838(22)02715-4. doi: 10.1016/j.eururo.2022.10.006

    paper

  • 702. Prostate Specific Antigen and Biopsy Contamination in the Goteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial

    Stinesen Kollberg S, Holmberg E, Josefsson A, Hugosson J, Arnsrud Godtman R, 2022

    Journal: J Urol
    Reference: 2022 Nov;208(5):1018-1027.

    paper

  • 701. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.

    Rijstenberg LL, Hansum T, Kweldam CF, Kummerlin IP, Remmers S, Roobol MJ, van Leenders GJLH., 2022

    Journal: Histopathology
    Reference: 2022 Jun;80(7):1041-1049. doi: 10.1111/his.14658.

    paper

  • 700. Secondary treatment for men with localized prostate cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform

    Beyer K, Straten V, Remmers S, MacLennan S, MacLennan S, Gandaglia G, Willemse PPM, Herrera R, Omar MI, Russell B, Huber J, Kreuz M, Asiimwe A, Abbott T, Briganti A, Van Hemelrijck M, Roobol MJ - The PRIAS consortium, the ERSPC Rotterdam Study Group, The PIONEER consortium., 2022

    Journal: J Pers Med.
    Reference: 2022 May 5;12(5):751. doi: 10.3390/jpm12050751.

    paper

  • 699. Detailed evaluation of androgen deprivation overtreatment in prostate cancer patients compared to the European Association of Urology guidelines using long-term data from the European Randomised Study of Screening for Prostate Cancer Rotterdam

    Hogenhout R, de Vos II, Remmers S, Venderbos LDF, Busstra MB, Roobol MJ, ERSPC Rotterdam Study Group, 2022

    Journal: Eur Urol Open Sci.
    Reference: 2022 Jul 2;42:42-49. doi: 10.1016/j.euros.2022.06.004.

    paper

  • 698. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/ml: the Finnish Randomized Study of Screening for Prostate Cancer

    Olasunmbo Ola I, Talala K, Tammela T, Taari K, Murtola T, Kujala P, Raitanen J, Auvinen A. , 2022

    Journal: Int J Cancer
    Reference: 2022 Sep 2. doi: 10.1002/ijc.34274.

    paper

  • 697. Allopurinol and prostate cancer survival in a Finnish population-based cohort

    Kukko V, Kaipa A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. , 2022

    Journal: Prostate Cancer Prostatic Dis.
    Reference: 2022 Sep 21. doi: 10.1038/s41391-022-00597-4.

    paper

  • 696. Results from 22 years of follow-up in the Göteborg Randomized Population-based Prostate Cancer Screening Trial

    Frånlund M, Månsson M, Arnsrud-Godtman R, Aus G, Holmberg E, Stinesen Kollberg K, Lodding P, Pihl C-G, Stranne J, Lilja H, Hugosson J, 2022

    Journal: J Urol
    Reference: 2022 Aug;208(2):292-300. doi: 10.1097/JU.0000000000002696. Epub 2022 Apr 15.

    paper

  • 695. The association between age, prostate cancer risk, and higher Gleason score in a long-term screening program: Results from the Göteborg-1 Prostate Cancer Screening Trial

    Arnsrud-Godtman R, Stinesen Kollberg K, Pihl C-G, Mansson M, Hugosson J. , 2022

    Journal: Eur Urol
    Reference: 2022 Sep;82(3):311-317. doi: 10.1016/j.eururo.2022.01.018. Epub 2022 Feb 1.

    paper

  • 694. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized study of Screening for Prostate Cancer

    Salminen JK, Mehtola A, Talala K, Taari K, Mäkinen J, Peltola J, Tammela TLJ, Auvinen A, Murtola TJ, 2022

    Journal: Br J Cancer
    Reference: 2022 May 3. Doi: 10.1038/s41416-022-01817-3

    paper

  • 693. Intervention-related deaths in the European Randomized study of screening for Prostate Cancer

    Arnsrud Godtman R, Remmers S, Aus G, Nelen V, van Eycken L, Villers A, Rebillard X, Kwiatkowski M, Wyler S, Puliti D, Gorini G, Paez A, Lujan M, Tammela T, Bangma CH, Auvinen A, Roobol MJ, 2021

    Journal: Eur Urol Open Science
    Reference: 34;27-32. doi.org/10.1016/j.euros.2021.09.014

    paper

  • 692. Outcomes of screening for prostate cancer among men using statins.

    Vettenranta A, Murtola TJ, Talala K, Taari K, Stenman U-H, Tammela TLJ, Auvinen A.,

    Journal: JAMA Oncology
    Reference: Accepted for publication, Aug 2021.

  • 691. Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized study of Screening for Prostate Cancer.

    Walter SD, Hu J, Talala K, Tammela T, Taari K, Auvinen A., 2021

    Journal: Cancer Causes Control
    Reference: Jul 27. doi:10.1007/s10552-021-01480-8.

    paper

  • 690. Outcomes of prostate cancer screening among men using antidiabetic medication

    Vettenranta A, Murtola TJ, Talala K, Taari K, Stenman U-H, Tammela TLJ, Auvinen A., 2021

    Journal: Sci Rep.
    Reference: Apr 1;11(1):7363. doi: 10.1038/s41598-021-86534-2.

    paper

  • 689. Digital rectal examination in screening for prostate cancer: long-term results from the Finnish randomized study of screening for prostate cancer (FinRSPC).

    Soronen V, Talala K, Raitanen J, Taari K, Tammela T, Auvinen A., 2021

    Journal: Scand J Urol
    Reference: 19;1-6. doi:10.1080/21681805.2021.1966095.

    paper

  • 688. Intraductal carcinoma has a minimal impact on grade group assignment in prostate cancer biopsy and radical prostatectomy specimens.

    Rijstenberg LL, Hansum T, Hollemans E, Kweldam CF, Kümmerlin IP, Bangma CH, van der Kwast TH, Roobol MJ, van Leenders GJLH., 2020

    Journal: Histopathology
    Reference: Nov;77(5):742-748. doi: 10.1111/his.14179.

    paper

  • 687. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: a micro-simulation study of 230 scenarios.

    Getaneh AM, Heijnsdijk EAM, Roobol MJ, de Koning HJ. , 2020

    Journal: Cancer Med
    Reference: Oct;9(20):7742-7750. doi: 10.1002/cam4.3395.

    paper

  • 686. Comparison of tumor volume parameters on prostate cancer biopsies.

    Verhoef EI, Kweldam CF, Kümmerlin IP, Nieboer D, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJLH., 2020

    Journal: Arch Pathol Lab Med
    Reference: Jan 6. doi: 10.5858/arpa.2019-0361-OA.

    paper

  • 685. Prostate cancer screening with magnetic resonance imaging: results from the second round of the Göteborg Prostate Cancer Screening 2 Trial

    Wallström J, Geterud K, Kohestani K, Maier SE, Pihl C-G, Socratous A, Stranne J, Arnsrud-Godtman R, Mansson M, Hellström M, Hugosson J, 2021

    Journal: Eur Urol Oncol
    Reference: Sep 24;S2588-9311(21)00153-X. doi:10.1016/j.euo.2021.09.001

    paper

  • 684. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.

    Peltomaa AI, Raittinen P, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. , 2021

    Journal: Prostate Cancer Prostatic Dis.
    Reference: Sep;24(3):917-924. doi: 10.1038/s41391-021-00351-2.

    paper

  • 683. Antidiabetic drugs and prostate cancer prognosis in a Finnish population-based cohort.

    Vihervuori VJ, Talala K, Taari K, Lahtela J, Tammela T, Auvinen A, Raittinen PVH, Murtola TJ. , 2021

    Journal: Cancer Epidemiol Biomarkers Prev
    Reference: Mar 2; cebp.0580.2019.

    paper

  • 682. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized study of Screening for Prostate Cancer.

    Salminen J, Kuoppamäki V, Talala K, Taari K, Mäkinen J, Peltola J, Tammela TLJ, Auvinen A, Murtola TJ. , 2021

    Journal: Int J Cancer
    Reference: Feb 26. doi: 10.1002/ijc.33535.

    paper

  • 681. Prognostic index for predicting prostate cancer survival in a randomized screening trial: Development and validation.

    Neupane S, Nevalainen J, Raitanen J, Talala K, Kujala P, Taari K, Tammela T, Steyerberg EW, Auvinen A. , 2021

    Journal: Cancers
    Reference: 13(3), 435; https://doi.org/10.3390/cancers13030435.

    paper

  • 680. Impact of cancer screening on metastasis: a prostate cancer case study

    Lange J, Remmers S, Gulati R, Bill-Axelson A, Johansson J-E, Kwiatkowski M, Auvinen A, Hugosson J, Hu JC, Roobol MJ, Carlsson SV, Etzioni R. , 2021

    Journal: J Med Screen
    Reference: Feb 9;969141321989738

    paper

  • 679. Prostate cancer risk prediction using a polygenic risk score

    Sipeky C, Talala K, Tammela TLJ, Taari K, Auvinen A, Schleutker J, 2020

    Journal: Sci Rep.
    Reference: Oct 13;10(1):17075. doi: 10.1038/s41598-020-74172-z.

    paper

  • 678. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish randomized study of screening for prostate cancer (FinRSPC)

    Pakarainen T, Nevalainen J, Talala K, Taari K, Raitanen J, Kujala P, Stenman U-H, Tammela TLJ, Auvinen A, 2021

    Journal: Cancer
    Reference: Jan 15;127(2):188-192. doi: 10.1002/cncr.33254.

    paper

  • 677. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men

    Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A, 2020

    Journal: PLoS One
    Reference: Jun 29;15(6):e0234269

    paper

  • 676. Long-term Health-Related Quality of Life among men with prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer

    Talala K, Heinävaara S, Taari K, Tammela TLJ, Kujala P, Stenman U-H, Malila N, Auvinen A, 2020

    Journal: Cancer Med
    Reference: 9(15):5643-5654 - doi: 10.1002/cam4.3181.

    paper

  • 675. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: results of the French section of European Randomized study of Screening for Prostate Cancer (ERSPC)

    Villers A, Bessaoud F, Tretarre B, Grosclaude P, Malavaud B, Rebillard X, Iborra F, Daubisse L, Malavaud S, Roobol MJ, Heijnsdijk EA, de Koning HJ, Hugosson J, Rischmann P, Soulie M., 2020

    Journal: Prog Urol
    Reference: Apr;30(5):252-260.

    paper

  • 674. Patients’ education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kilpeläinen TP, Talala K, Taari K, Raitanen J, Kujala P, Pylväläinen J, Tammela TL, Auvinen A., 2020

    Journal: Eur J Cancer
    Reference: Mar 28;130:204-210.

    paper

  • 673. Long-term outcomes for men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: a Population-based Cohort

    Palmstedt, Mansson M, Franlund M, Stranne J, Pihl CG, Hugosson J, Arnsrud Godtman R, 2019

    Journal: Eur Urol Oncol
    Reference: 2019 Nov;2(6):716-722. doi: 10.1016/j.euo.2019.01.016.

    paper

  • 672. Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau)

    Prause LW, Manka L, Millan C, Lang E, Wyler SF, Grobholz R, Hammerer-Lercher, Sulser T, Recker F, Kwiatkowski M, Eberli D, 2019

    Journal: World J Urol
    Reference: Doi: 10.1007/s00345-019-03054-5

    paper

  • 671. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.

    Booth N, Rissanen P, Tammela TLJ, Kujala P, Stenman U-H, Taari K, Talala K, Auvinen A. , 2019

    Journal: PLOS ONE
    Reference: https://doi.org/10.1371/journal.pone.0224479

    paper

  • 670. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.

    Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A., 2019

    Journal: Cancer Causes & Control
    Reference: (2019) 30:877-888.

    paper

  • 669. The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers.

    Heijnsdijk EAM, Adolfsson J, Auvinen A, Roobol MJ, Hugosson J, De Koning HJ, 2019

    Journal: European Urology
    Reference: 76 (2019):276-279.

    paper

  • 668. Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer.

    Remmers S, Verbeek JFM, Nieboer D, Van der Kwast Th, Roobol MJ, 2019

    Journal: BJU International
    Reference: doi:10.1111/bju.14790

    paper

  • 667. Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time.

    Pylväläinen J, Talala K, Murtola T, Taari K, Raitanen J, Tammela T, Auvinen A. , 2019

    Journal: Clinical Epidemiology
    Reference: 11:923-932.

    paper

  • 666. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized study of Screening for Prostate Cancer Risk Calculators

    Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C, 2019

    Journal: Eur Urol
    Reference: 2019 Feb;75(2):310-318.

    paper

  • 665. The ERSPC study: quality takes time and perseverance

    Roobol MJ, Carlsson SV, 2019

    Journal: Clin Chem
    Reference: 2019 Jan; 65(1):208-209

    paper

  • 664. Results of prostate cancer screening in a unique cohort at 19yr of follow-up

    Osses DF, Remmers S, Schröder FH, van der Kwast T, Roobol MJ, 2019

    Journal: Eur Urol
    Reference: 2019 Mar;75(3):374-377

    paper

Next →